my account
Login
  Loading... Please wait...

Product Details

Duvelisib | PI3Kdelta/gamma inhibitor

Duvelisib (1201438-56-3) is a potent and selective (IC50’s: PI3Kα = 1602nM, PI3Kβ = 85nM, PI3Kδ= 2.5nM, PI3Kγ = 27nM) dual PI3Kδ/γ inhibitor.1 It inhibits B and T cell proliferation, blocks neutrophil migration, and inhibits basophil activation. Duvelisib antagonizes B-cell receptor crosslinking activated pro-survival signals in primary chronic lymphocytic leukemia cells.2 Duvelisib also shows preclinical/clinical activity against other hematologic malignancies such as Non-Hodgkins lymphoma, T-cell lymphoma, and others.3,4 Useful clinical agent for the treatment of various blood cancers. Low-dose treatment of T-cell-inflamed tumor models of head and neck cancers with Duvelisib enhanced responses to PD-L1 blockade via suppression of myeloid-derived suppressor cells.5 Higher doses reversed the effect due to suppression of tumor-infiltrating T lymphocytes

References/Citations

1) Winkler et al. (2013), PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Response and Suppresses Activity in Autoimmune and Inflammatory Disease Models; Chem. Biol. 20 1309
2) Dong et al. (2014), IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells; Blood 124 3583
3) Flinn et al. (2018), Duvelisib, a novel dual inhibitor of PI3K-δ/γ, is clinically active in advances hematologic malignancies; Blood 131 877
4) Faia et al. (2018), The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib, shows preclinical synergy with multiple targeted therapies in hematologic malignancies; PLoS One 13 e0200725
5) Davis et al. (2017), Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ; Cancer Res. 77 2607

swipe
Image 1

Catalog#  10-4788-0005

$75.00
Quantity
Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee.
 
Request Bulk Quote
CAS:
1201438-56-3
Catalog Number:
10-4788
Activity:
PI3Kδ/γ inhibitor/Cancer immunotherapy enhancer
Chemical Name:
8-Chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one
Alternative Name:
IPI-145
Molecular Weight:
416.87
Molecular Formula:
C22H17ClN6O
Solubility:
Soluble in DMSO (up to at least 25 mg/ml)
Physical Properties:
White solid
Purity:
98% by HPLC
NMR (Conforms)
Storage Temperature:
-20°C (des.)
Stability:
Stable for 1 year as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
Shipping Code:
RT
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.

Focus BiomoleculesPlymouth Meeting, PA USA1-855-FOCUS21

Connect with Focus

Click the button below to add the Duvelisib | PI3Kdelta/gamma inhibitor to your wish list.